Outcome of patients with soft tissue sarcomas of the extremities and trunk treated by (neo)adjuvant intensity modulated radiation therapy with curative intent.
Extremities & trunk
Intensity-modulated radiotherapy
Soft tissue sarcoma
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
08
09
2022
accepted:
25
02
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Soft tissue sarcomas (STS) are a relatively rare group of malignant tumors. Currently, there is very little published clinical data, especially in the context of curative multimodal therapy with image-guided, conformal, intensity-modulated radiotherapy. Patients who received preoperative or postoperative intensity-modulated radiotherapy for STS of the extremities or trunk with curative intent were included in this single centre retrospective analysis. A Kaplan-Meier analysis was performed to evaluate survival endpoints. Multivariable proportional hazard models were used to investigate the association between survival endpoints and tumour-, patient-, and treatment-specific characteristics. 86 patients were included in the analysis. The most common histological subtypes were undifferentiated pleomorphic high-grade sarcoma (UPS) (27) and liposarcoma (22). More than two third of the patients received preoperative radiation therapy (72%). During the follow-up period, 39 patients (45%) suffered from some type of relapse, mainly remote (31%). The two-years overall survival rate was 88%. The median DFS was 48 months and the median DMFS was 51 months. Female gender (HR 0.460 (0.217; 0.973)) and histology of liposarcomas compared to UPS proved to be significantly more favorable in terms of DFS (HR 0.327 (0.126; 0.852)). Conformal, intensity-modulated radiotherapy is an effective treatment modality in the preoperative or postoperative management of STS. Especially for the prevention of distant metastases, the establishment of modern systemic therapies or multimodal therapy approaches is necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Soft tissue sarcomas (STS) are a relatively rare group of malignant tumors. Currently, there is very little published clinical data, especially in the context of curative multimodal therapy with image-guided, conformal, intensity-modulated radiotherapy.
METHODS
METHODS
Patients who received preoperative or postoperative intensity-modulated radiotherapy for STS of the extremities or trunk with curative intent were included in this single centre retrospective analysis. A Kaplan-Meier analysis was performed to evaluate survival endpoints. Multivariable proportional hazard models were used to investigate the association between survival endpoints and tumour-, patient-, and treatment-specific characteristics.
RESULTS
RESULTS
86 patients were included in the analysis. The most common histological subtypes were undifferentiated pleomorphic high-grade sarcoma (UPS) (27) and liposarcoma (22). More than two third of the patients received preoperative radiation therapy (72%). During the follow-up period, 39 patients (45%) suffered from some type of relapse, mainly remote (31%). The two-years overall survival rate was 88%. The median DFS was 48 months and the median DMFS was 51 months. Female gender (HR 0.460 (0.217; 0.973)) and histology of liposarcomas compared to UPS proved to be significantly more favorable in terms of DFS (HR 0.327 (0.126; 0.852)).
CONCLUSION
CONCLUSIONS
Conformal, intensity-modulated radiotherapy is an effective treatment modality in the preoperative or postoperative management of STS. Especially for the prevention of distant metastases, the establishment of modern systemic therapies or multimodal therapy approaches is necessary.
Identifiants
pubmed: 36869396
doi: 10.1186/s13014-023-02238-z
pii: 10.1186/s13014-023-02238-z
pmc: PMC9985237
doi:
Substances chimiques
Adjuvants, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Informations de copyright
© 2023. The Author(s).
Références
Cancer. 2013 May 15;119(10):1878-84
pubmed: 23423841
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1196-203
pubmed: 18207661
Oncol Res Treat. 2020;43(5):189-195
pubmed: 32268331
J Surg Oncol. 2019 Sep;120(3):325-331
pubmed: 31172531
Pathologica. 2021 Apr;113(2):70-84
pubmed: 33179614
Pract Radiat Oncol. 2021 Sep-Oct;11(5):339-351
pubmed: 34326023
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Lancet. 1997 Dec 6;350(9092):1647-54
pubmed: 9400508
N Engl J Med. 2005 Aug 18;353(7):701-11
pubmed: 16107623
Chest. 2005 Mar;127(3):902-8
pubmed: 15764774
Ann Oncol. 2010 Oct;21 Suppl 7:vii265-9
pubmed: 20943625
Oncologist. 2017 Nov;22(11):1400-1410
pubmed: 28739867
Ann Surg Oncol. 2022 Feb 27;:
pubmed: 35224688
Eur J Cancer. 2014 Dec;50(18):3178-86
pubmed: 25459395
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):203-9
pubmed: 19679403
J Clin Oncol. 2020 Oct 20;38(30):3555-3564
pubmed: 32840417
Curr Treat Options Oncol. 2015 Mar;16(3):328
pubmed: 25777573
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e525-8
pubmed: 21676552
Radiat Oncol. 2016 Oct 12;11(1):136
pubmed: 27733179
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):572-80
pubmed: 22520481
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
BMC Public Health. 2018 Feb 12;18(1):235
pubmed: 29433465
Eur J Cancer. 2000 Apr;36(6):710-6
pubmed: 10762742
Medicine (Baltimore). 2020 May 22;99(21):e20165
pubmed: 32481285
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1604-1612
pubmed: 33285515
Am J Clin Oncol. 2003 Aug;26(4):411-5
pubmed: 12902897
Clin Sarcoma Res. 2016 Nov 15;6:20
pubmed: 27891213
Ann Oncol. 2014 Sep;25(9):1854-1860
pubmed: 24914041
Int J Mol Sci. 2018 Mar 05;19(3):
pubmed: 29510588
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Cancer. 2001 May 15;91(10):1914-26
pubmed: 11346874
Diagn Cytopathol. 2016 Apr;44(4):351-60
pubmed: 26780171